[CELG] Celgene Corporation


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 78.56 B

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 118.93 Change: 1.06 (0.9%)
Ext. hours: Change: 0 (0%)

chart CELG

Refresh chart

Strongest Trends Summary For CELG

CELG is in the long-term down -28% in 2 years and up 1061% in 26 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and immune-inflammatory related diseases in the United States and internationally. The company?s commercial stage products include REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, as well as acute myeloid leukemia (AML); ABRAXANE, a solvent-free chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; and POMALYST/IMNOVID for the treatment of multiple myeloma. Its commercial stage products also comprise THALOMID for the patients with multiple myeloma and for the acute treatment of the cutaneous manifestations of erythema nodosum leprosum; ISTODAX to treat cutaneous T-cell lymphoma; and FOCALIN, FOCALIN XR, and RITALIN LA products. The company?s

Fundamental Ratios
Shares Outstanding774.6 M EPS3.09 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 14.91% Sales Growth - Q/Q9.47% P/E39.6
P/E To EPS Growth P/S9.32 P/BV12.43 Price/Cash Per Share10.49
Price/Free Cash Flow29.58 ROA12.38% ROE34.76% ROI15.22%
Current Ratio3.34 Quick Ratio3.2 Long Term Debt/Equity0.9 Debt Ratio0.47
Gross Margin95.19% Operating Margin31.72% Net Profit Margin26.08% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-951.3 M Cash From Investing Activities239.7 M Cash From Operating Activities1.14 B Gross Profit2.18 B
Net Profit356.2 M Operating Profit412.4 M Total Assets17.75 B Total Current Assets9.88 B
Total Current Liabilities2.96 B Total Debt7.62 B Total Liabilities11.42 B Total Revenue2.28 B
Technical Data
High 52 week106.68 Low 52 week59.21 Last close87.3 Last change-1.05%
RSI92.09 Average true range3.5 Beta1.08 Volume2.51 M
Simple moving average 20 days16.39% Simple moving average 50 days20.46% Simple moving average 200 days6.62%
Performance Data
Performance Week-0.24% Performance Month28.01% Performance Quart6.68% Performance Half1.69%
Performance Year-16.71% Performance Year-to-date36.21% Volatility daily4.73% Volatility weekly10.58%
Volatility monthly21.69% Volatility yearly75.13% Relative Volume218.43% Average Volume9.4 M
New High New Low


2019-03-21 10:03:02 | Bristol-Myers' Celgene Buyout Still Uncertain Amid Opposition

2019-03-21 07:30:00 | Proxy Advisors Could Tilt the Scales in the Bristol-Celgene Deal. Watch for Their Calls Next Week.

2019-03-20 16:16:41 | Amid Bristol-Starboard Duel Over Celgene, Here's What's Really Key

2019-03-20 11:24:03 | Emergent Begins Phase III Study on Anthrax Vaccine AV7909

2019-03-20 08:55:12 | Buy These 5 ROE Stocks as Stock Market Euphoria Continues

2019-03-20 08:32:12 | The Zacks Analyst Blog Highlights: Hilton, Xilinx, Quanta, Anthem and Celgene

2019-03-19 21:33:00 | Starboard vs. Bristol-Myers Squibb: Who'll Win This Brewing Battle?

2019-03-19 18:18:36 | [$$] If This Is Failure, Show Me Success

2019-03-19 17:53:09 | Puma Biotech's PBYI Nerlynx Gets Approval in Australia

2019-03-19 15:17:06 | Analysts Have Revised BMY’s Target Price Downward in March

2019-03-19 14:26:06 | Catalyst CPRX Reports Wider Q4 Loss, Focuses on Firdapse

2019-03-19 14:17:00 | Starboard Is Against the Bristol-Myers and Celgene Deal. Now It Gets Interesting.

2019-03-19 13:14:00 | Bristol-Myers Pushes Celgene Deal, Starboard Hits Back, in $74B Takeover Spat

2019-03-19 11:57:03 | PhaseBio Stock Up on Positive Data From PB2452 Phase I Study

2019-03-19 11:51:03 | Allergan's Anti-Infective Gets FDA Nod for Pediatric Patients

2019-03-19 11:24:00 | Why Shareholders Should Vote for Bristol-Myers Celgene Deal: Jim Cramer

2019-03-19 10:48:00 | Jim Cramer: Tilray's Earnings, Bristol-Myers and Celgene and Elon Musk

2019-03-19 09:53:00 | Jim Cramer Breaks Down Tilray Earnings, Elon Musk's Twitter and Bristol-Myers

2019-03-19 09:52:01 | Are Americans More Confident in 2019? 5 Top Picks

2019-03-19 09:50:08 | See what the IHS Markit Score report has to say about Celgene Corp.

2019-03-19 09:45:11 | Bristol-Myers Squibb and Starboard Value square off over Celgene deal

2019-03-18 18:44:10 | Bristol-Myers & Pfizer Release Phase IV Data on Eliquis

2019-03-18 17:45:09 | Celgene CELG Stock Sinks As Market Gains: What You Should Know

2019-03-18 09:30:01 | Is Celgene CELG Outperforming Other Medical Stocks This Year?

2019-03-18 08:06:12 | AstraZeneca Up This Year on New Drugs & Pipeline Progress

2019-03-18 07:25:11 | Lexicon Pharma Initiates Dosing in Biliary Tract Cancer Study

2019-03-18 06:23:10 | Bear of the Day: Gilead Sciences GILD

2019-03-15 16:04:08 | Roche Gets Approval for Label Expansion of MabThera in Europe

2019-03-15 14:00:00 | Is Celgene and Bristol-Myers a Match Made in Heaven or Doomed to Fail?

2019-03-15 11:38:03 | AVEO Pharmaceuticals AVEO Q4 Earnings Beat, Revenues Lag

2019-03-15 11:25:03 | PDL BioPharma PDLI Q4 Earnings Top Mark, Revenues Fall Y/Y

2019-03-15 05:05:09 | J&J Seeks Approval for Darzalex in Expanded Patient Group

2019-03-14 17:15:08 | Washington Health Care Facilities Auth -- Moody's upgrades Fred Hutchinson Cancer Research Center WA to A2 from A3; outlook stable

2019-03-14 16:24:15 | Key Celgene Issue That Could 'Unnerve' Bristol Takeover Was Just Tossed

2019-03-14 11:20:03 | Puma Biotech PBYI Up More Than 95% in 3 Months: Here's Why

2019-03-14 11:13:03 | Agenus Wins $7.5M Milestone Payment From Gilead, Stock Up

2019-03-14 09:32:49 | U.S. court rejects Alvogen's patent challenge for Celgene's cancer drug

2019-03-14 09:09:23 | U.S. patent court rejects Alvogen's challenge for Celgene's Revlimid

2019-03-14 08:21:12 | Top Ranked Value Stocks to Buy for March 14th

2019-03-13 17:31:31 | 5 Biotech Stocks to Keep an Eye on in 2019

2019-03-13 16:37:00 | Celgene’s Positive Drug Data Bolsters Bristol-Myers Deal, Analyst Says

2019-03-13 16:17:23 | Does This Celgene-Roche Approval Sweeten The Pot For Bristol?

2019-03-13 12:50:04 | Aerie AERI Receives FDA Nod for Rocklatan to Treat Glaucoma

2019-03-13 10:46:02 | Biotech Stock Roundup: REGN Gets FDA Nod for Dupixent & Other Pipeline News

2019-03-13 09:30:01 | CELG vs. VRTX: Which Stock Is the Better Value Option?

2019-03-13 09:11:01 | Zacks.com featured expert Kevin Matras highlights: Sallie Mae, United Continental, Celgene and Ligand Pharmaceuticals

2019-03-12 16:59:28 | How This Looming Patent Battle Could Challenge Bristol-Celgene Deal

2019-03-12 16:30:00 | Celgene Provides Update on ABRAXANE® Combination Therapy in the Treatment of Metastatic Triple-Negative Breast Cancer and Pancreatic Cancer

2019-03-12 15:22:07 | Regeneron/Sanofi's Dupixent Gets FDA Nod for Label Expansion

2019-03-12 10:30:54 | See what the IHS Markit Score report has to say about Celgene Corp.